Amrinone (Amrinon)

Subscribe to Selected New Research on Amrinone

330 relevant articles (49 outcomes, 55 trials/studies) found for this Drug

Description: A positive inotropic cardiotonic (CARDIOTONIC AGENTS) with vasodilator properties, phosphodiesterase inhibitory activity, and the ability to stimulate calcium ion influx into the cardiac cell.

Also Known As:

Amrinon; Inocor; 5-Amino-(3,4'-bipyridine)-6(1H)-one; Cordemcura; LAW Brand of Amrinone; Sanofi Brand of Amrinone Lactate; Sanofi Winthrop Brand of Amrinone; Sanofi Winthrop Brand of Amrinone Lactate; Win-40680; Wincoram; Amrinone LAW Brand; Win 40680; Win40680; (3,4'-Bipyridin)-6(1H)-one, 5-amino-

Relationship Network

Drug Context: Research Results

Organic Chemicals: 40

Heterocyclic Compounds: 23

1-Ring Heterocyclic Compounds

Experts

1.	Martin, E: 2 articles (09/2000 - 09/2000)
2.	Schmidt, W: 2 articles (09/2000 - 09/2000)
3.	Gebhard, M M: 2 articles (09/2000 - 09/2000)
4.	Schmidt, H: 2 articles (09/2000 - 09/2000)
5.	Tinelli, M: 2 articles (09/2000 - 09/2000)
6.	Komamura, Kazuo: 1 article (03/2008)
7.	Matsuo, Hiroshi: 1 article (03/2008)
8.	Sasaki, Tatsuya: 1 article (03/2008)
9.	Gong, Su-Gang: 1 article (06/2007)
10.	Liu, Jing-Ming: 1 article (06/2007)

Related Diseases

1.	Heart Failure 05/01/1985 - "A number of uncontrolled studies have indicated that oral administration of amrinone, a phosphodiesterase inhibitor with potent positive inotropic effects in experimental preparations, may be beneficial in patients with chronic congestive heart failure" 07/22/1985 - "Animal and human studies suggest that amrinone can cause significant improvement in the systemic hemodynamics of patients with severe congestive heart failure (CHF), and do so without increasing myocardial oxygen consumption" 07/01/1981 - "Amrinone, a new inotropic agent, has been shown to be beneficial in patients with congestive heart failure" 11/01/1984 - "Failure of low doses of amrinone to produce sustained hemodynamic improvement in patients with severe chronic congestive heart failure." 03/01/1987 - "Thus, intravenous amrinone proved effective in patients with severe heart failure, with maximal effects being obtained in doses of 3 mg X min-1." Get all the results and reference details, order at left...
2.	Pulmonary Hypertension (Ayerza Syndrome) 09/01/1986 - "The aim of this study was to investigate the haemodynamic effects of amrinone in patients with pulmonary hypertension and impaired right ventricular function" 08/01/1996 - "Lungs were examined for immunohistochemical evidence of PDGF and bFGF, and hearts were examined for effects of pulmonary hypertension and amrinone" 11/01/1993 - "Effect of amrinone during group B Streptococcus-induced pulmonary hypertension in piglets." 11/01/1993 - "Amrinone therapy for severe pulmonary hypertension and biventricular failure after complicated valvular heart surgery." 10/01/1993 - "The sole child with postoperative pulmonary hypertension had a beneficial decrease in pulmonary artery pressure, increase in cardiac index, and stable systemic blood pressure during amrinone use" Get all the results and reference details, order at left...
3.	Low Cardiac Output 01/01/1991 - "The efficacy of amrinone was assessed in the treatment of low cardiac output states occurring within 24 h after mitral valve replacement in an open prospective trial" 01/01/1991 - "Hemodynamic effects of amrinone in low cardiac output after mitral valve replacement]" 08/01/1990 - "Amrinone in perioperative low cardiac output syndrome." 12/01/1989 - "Amrinone: contemporary management of the low cardiac output syndrome" 07/01/1988 - "Clinical and hemodynamic multicenter study of the effect of intravenous amrinone in the treatment of low cardiac output after valvular replacement]" Get all the results and reference details, order at left...
4.	Coronary Artery Disease (Coronary Atherosclerosis) 05/01/1994 - "We have studied the effects of amrinone on left and right ventricular haemodynamics in patients with impaired ventricular performance caused by coronary artery disease" 12/01/1986 - "Peripheral hemodynamics and metabolic parameters were studied in 12 healthy volunteers (mean = 24.6 years) and in 12 patients with coronary artery disease (mean = 51.1 years) at rest and after isometric handgrip exercise both before and after application of amrinone (1.5 mg/kg body weight i.v.)" 07/01/1980 - "Accordingly, the hemodynamic, myocardial metabolic and ECG responses to amrinone (2.5 mg/kg i.v. over 1 hour) were measured in nine patients with congestive heart failure secondary to coronary artery disease" 07/01/1980 - "Effects of amrinone on myocardial energy metabolism and hemodynamics in patients with severe congestive heart failure due to coronary artery disease." 07/01/1980 - "The amrinone-induced hemodynamic improvement in patients with congestive heart failure secondary to coronary artery disease was associated with reductions in MVO2 and CBF and no evidence of myocardial ischemia." Get all the results and reference details, order at left...
5.	Myocardial Ischemia (Ischemic Heart Diseases) 02/01/1987 - "The effect of the positive inotropic agent amrinone on anatomic infarct size induced by coronary artery occlusion and reperfusion in dogs is unknown, although previous studies have shown that amrinone increases indices of myocardial ischemia during very brief coronary artery occlusions" 12/01/1993 - "The effects of amrinone (CAS 60719-84-8) (10(-6) mol/l or 5 x 10(-5) mol/l) or milrinone (CAS 78415-72-2) 10(-5) mol/l) on myocardial ischemia extent and infarct size were compared in isolated electrically paced rabbit hearts (Langendorff, constant pressure: 70 cm H2O, Tyrode solution, Ca2+ 1.8 mmol/l)" 12/01/1993 - "Effect of amrinone and milrinone on myocardial ischemia extent and infarct size in isolated rabbit hearts." 10/01/1992 - "The incidence of myocardial ischemia as detected by Holter monitor was 36% with amrinone and 33% with dobutamine" 12/01/1984 - "Clinically, amrinone therapy was complicated by sustained symptomatic ventricular tachycardia in four patients, worsening myocardial ischemia in four patients, and worsening congestive heart failure in eight patients, all of whom had been stable before entry into the study; only three of the 31 patients improved clinically" Get all the results and reference details, order at left...
108 Diseases and 330 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Dobutamine
2.	Milrinone (Primacor)
3.	Type 3 Cyclic Nucleotide Phosphodiesterases
4.	Epinephrine (Adrenaline)
5.	Vasodilator Agents (Vasodilators)
6.	pirbuterol (Maxair)
7.	Carbon Monoxide
8.	Prenalterol
9.	vesnarinone
10.	Albuterol (Salbutamol)
120 Drugs and Important Bio-Agents and 166 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Cardiopulmonary Bypass (Heart-Lung Bypass)
2.	Transplants (Transplant)
3.	Coronary Artery Bypass (Coronary Artery Bypass Surgery)
4.	Aftercare (After-Treatment)
5.	Resuscitation
17 Therapies and Procedures and 28 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>